Cargando…
CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert strong anti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974902/ https://www.ncbi.nlm.nih.gov/pubmed/35402810 http://dx.doi.org/10.1097/BS9.0000000000000028 |